From the Editor

The generalist’s dilemma: training and staying current in the face of increasing specialization


 

So, let me ask you a question: How do you stay up-to-date in oncology and hematology? In particular, are you at an academic institution or in community practice? Do you do only oncology, or is your focus oncology and hematology? If you are in an academic institution, you probably are highly specialized in one tumor type. If your practice is in a community setting, you probably treat a range of cancer types as well as hematology. Throw into this mix the fact that new therapies and new indications for existing drugs are being approved, and that guidelines are routinely updated, and you realize the tremendous pressure you’re under to stay current, whether you’re a specialist or a generalist.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Elotuzumab plus len-dex extends remissions of multiple myeloma
MDedge Hematology and Oncology
Familial factors linked to child’s risk of blood cancer
MDedge Hematology and Oncology
Team links telomere degeneration and MDS
MDedge Hematology and Oncology
Explaining obesity in cancer survivors
MDedge Hematology and Oncology
Inhibitor may benefit certain ALL patients
MDedge Hematology and Oncology
Protein linked to leukemia, breast cancer
MDedge Hematology and Oncology
Drug can alleviate transfusion dependence in non-del-5q MDS
MDedge Hematology and Oncology
Tool identifies CNAs other algorithms miss
MDedge Hematology and Oncology
Inhibitor gets breakthrough designation for CLL
MDedge Hematology and Oncology
Agent preferentially targets FLT3-ITD AML
MDedge Hematology and Oncology